Cancer-Associated Antigen CA 195 in Patients with Mucinous Ovarian Tumours: A Comparative Analysis with CEA, TATI and CA 125 in Serum Specimens and Cyst Fluids
作者:
H.W.A. de Bruijn,
K.A. ten Hoor,
H. Boonstra,
J. Marrink,
M. Krans,
J.G. Aalders,
期刊:
Tumor Biology
(Karger Available online 1993)
卷期:
Volume 14,
issue 2
页码: 105-115
ISSN:1010-4283
年代: 1993
DOI:10.1159/000217863
出版商: S. Karger AG
关键词: Mucinous ovarian tumours;Cyst fluid;Tumour-associated antigen CA195;Tumour-associated trypsin inhibitor;Carcinoembryonic antigen;Cancer antigen CA 125
数据来源: Karger
摘要:
The CA 195 levels in ovarian cyst fluids from malignant mucinous tumours (median 2,300,000 U/ml) were significantly higher than the levels in benign mucinous tumours and malignant non-mucinous tumours (medians of 26,800 and 1,700 U/ml, respectively, p = 0.039 and 0.011). Also, the carcinoembryonic antigen (CEA) and tumour-associated trypsin inhibitor (TATI) levels in cyst fluid from mucinous tumours were much higher than those in non-mucinous tumours. Pre-treatment serum CA 195 levels were found to be elevated ( > 10.5 U/ml) in 72% of the patients with malignant mucinous tumours (n = 25), compared with 35% in malignant non-mucinous tumours and 28% in benign mucinous tumours. The positivity rate shown for serum CA 195 in malignant mucinous tumours was higher than that measured for serum TATI, CA 125 or CEA (60, 53 and 42%, respectively). Measurement of serum CA 195 can be valuable in the clinical management of patients with mucinous ovarian cancer.
点击下载:
PDF
(3298KB)
返 回